About the Company
We do not have any company description for Kalaris Therapeutics, Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Kalaris Therapeutics, Inc.
Kalaris Reports Second Quarter 2025 Financial Results and Provides Business Updates
Continuing to enroll nAMD patients in a Phase 1 trial of TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased anti-VEGF activity to treat ...
Kalaris Therapeutics Elects New Directors at Annual Meeting
Kalaris Therapeutics ( ($KLRS) ) just unveiled an announcement. At the 2025 Annual Meeting of Stockholders held on August 12, 2025, Kalaris ...
Kalaris Reports First Quarter 2025 Financial Results and Provides ...
PALO ALTO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization ...
Kalaris Therapeutics, Inc. Common Stock (KLRS) SEC Filings
Mar 23, 2025 Nasdaq Listed Market: Closed Kalaris Therapeutics, Inc. Common Stock (KLRS) Volume: 40,759 52 Week Range: 7.96 - 24.15 ...
Kalaris Announces Closing of Merger with AlloVir
PALO ALTO, Calif., March 18, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS)(“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and ...
Kalaris Therapeutics appoints new board chair - Investing.com
PALO ALTO, Calif. - Kalaris Therapeutics, Inc. (NASDAQ:KLRS), a biopharmaceutical company focused on retinal disease treatments, announced today the addition of Leone Patterson to its Board of ...
Kalaris and AlloVir Announce Stockholder Approval of Merger
PALO ALTO, Calif. and LEXINGTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and ...
Kalaris Therapeutics Inc. (KLRS) Stock Price Today - WSJ
View the latest Kalaris Therapeutics Inc. (KLRS) stock price, news, historical charts, analyst ratings and financial information from WSJ.
Kalaris Therapeutics Inc. Share Price (KLRS.US)
Kalaris Therapeutics Inc. is listed on the CBOE trading with ticker code KLRS.US. It has a market capitalisation of $46.76m, with approximately 18.70m shares in issue. Over the last year, Kalaris ...
Kalaris Therapeutics, Inc. Common Stock - Nasdaq
Find the latest institutional holdings data for Kalaris Therapeutics, Inc. Common Stock (KLRS) including shareholders, ownership summaries, and holding activities at Nasdaq.com.
Kalaris Therapeutics, Inc.: Kalaris Reports Second Quarter 2025 Financial Results and Provides Business Updates
Continuing to enroll nAMD patients in a Phase 1 trial of TH103, a novel, differentiated anti-VEGF agent engineered to ...
Similar Companies
Loading the latest forecasts...